Management Team

Dr. Rekdal is Co-founder of and served as CEO during the first 4 years of Lytix Biopharma's formation.

After that he served as CSO and Head of R&D before he again was promoted to the position of CEO in 2018. Rekdal's research background is within tumor immunology and his field of expertise is anticancer molecules derived from host defense peptides. Dr. Rekdal commenced his PhD on cytolysis and tumor immunology in 1990, and his postdoctoral work forms the basis of Lytix Biopharma's technology peptide platform.

Dr. Rekdal has been instrumental in establishing collaborations with several distinguished researchers and institutions and is regularly invited to give plenary lectures at international oncology, industry and partnering conferences.

Mr. Breistein has extensive experience as an auditor and consultant. Prior to joining Lytix in 2017, he worked at PwC advising public and private companies across multiple industry sectors in capital market transactions, financing and listing processes.

Mr. Breistein is a state authorized public accountant, and holds a Masters in Applied Economics and Finance from Copenhagen Business School as well as a Masters in Professional Accountancy from the Norwegian School of Management.

Dr. Sveinbjørnsson achieved his doctorate at the Medical Faculty of the University of Tromsø in 1998, with a focus on mechanisms and mediators behind immunomodulation of experimental tumors. Since then, Dr. Sveinbjørnsson has gained a broad expertise of preclinical oncology at the University of Tromsø and Karolinska Institut Stockholm.

Dr. Sveinbjørnsson has been involved in the research activities of Lytix Biopharma since the beginning, and has most recently led the Company's research activities as Chief Scientific Officer.

Dr. Mette Husbyn brings over 16 years of experience at GE Healthcare, where she held various scientific and managerial roles covering all aspects of CMC, from pre-clinical and early clinical phases to commercial products.

Following her tenure at GE, Dr. Husbyn served as Head of CMC at Lytix Biopharma from 2012 to 2017, where she oversaw all CMC activities and established robust processes to enhance drug development.

Most recently she held the position of Head of CMC and CTO at Xylonix Therapeutics, leading a team of 22 professionals focused on strategic partner selection, process development, and regulatory interactions across the UK and Europe.

Dr. Husbyn earned her doctorate from the Medical Faculty of the University of Oslo in 2003, specializing in peptide chemistry.

Dr. Benhadji brings over 20 years of experience in biopharmaceutical oncology drug development. Most recently, he served as Chief Medical Officer at Inspirna and GV20 Therapeutics.

Previously, he was Senior Vice President and Head of Clinical Development and Operations at Taiho Oncology, where he led the development of both early- and late-phase portfolio assets. His leadership led to the FDA approval of LYTGOBI® (futibatinib) for cholangiocarcinoma and supported the Phase 3 SUNLIGHT trial, which led to the FDA approval of LONSURF® (trifluridine/tipiracil) in combination with bevacizumab for metastatic colorectal cancer.

Earlier in his career, Dr. Benhadji spent 13 years at Eli Lilly and Company in oncology development roles of increasing responsibility, including oversight of several immuno-oncology programs.

Dr. Benhadji earned his M.D. from the University of Oran and completed his oncology fellowship at the Universities of Oran and Paris. He also holds a Master of Science in Pharmacology and Therapeutics in Oncology from the University of Paris.

Mr. Meadows has more than 25 years experience in biopharmaceutical strategy and business development leadership roles. Most recently Mr. Meadows served as CBO at Oncodex, where he defined the company's overall business strategy and oversaw all aspects of business development and partnering, including deal execution. He has also held senior-level positions in business development, commercial strategy and global marketing at Theragnostics, Bristol Myers Squibb, Biogen and Johnson and Johnson. While at AVRO Oncology and NanoString, he co-led multiple transactions each worth over $1 billion, transforming these oncology businesses.

He holds a Masters in Business Administration from Babson College and a Bachelors in Science in Finance from the University of Richmond.